Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.006 USD | +1.21% | -2.08% | -7.93% |
Apr. 24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
Apr. 08 | Gain Therapeutics Names Gene Mack as CFO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.12% | 53.61M | |
+24.93% | 42.68B | |
-3.14% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.22% | 24.94B | |
-20.16% | 18.96B | |
+28.88% | 12.3B | |
-2.82% | 11.95B | |
-1.52% | 11.55B |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.
- HC Wainwright Trims Price Target on Gain Therapeutics to $9 From $10, Keeps Buy Rating